The effectiveness of intimate biorevitalization in the treatment of symptoms of vulvovaginal atrophy
- Authors: Saidova A.S.1, Dudkina A.R.1, Teterina T.A.1, Apolikhina I.A.1,2
-
Affiliations:
- V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
- Sechenov University
- Issue: Vol 30, No 4/5 (2023)
- Pages: 96-103
- Section: Original articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/568048
- DOI: https://doi.org/10.18565/pharmateca.2023.4-5.96-103
- ID: 568048
Cite item
Open Access
Access granted
Abstract
Background. The problems of women’s reproductive aging and the need to maintain and improve the quality of life and health of women during the period of age-related changes are an urgent task of modern medicine, especially in the light of existing demographic trends. Genitourinary menopausal syndrome (GUMS) is a symptom complex that occurs in women against the background of a deficiency of estrogens and other sex steroids, including physiological and anatomical changes in the vagina, urethra, bladder, vulva and perineum.
Objective. Evaluation of the effectiveness of vulva biorevitalization with preparations based on hyaluronic acid (HA) in combination with hardware methods for the relief of local symptoms of GUMS and lichen sclerosus (LS).
Methods. The study included 40 patients: 20 with GUMS (group 1) and 20 with LS (group 2). The follow-up period was up to 6 months. Patients aged 24–65 years were included, the median age of patients in both groups was 42 years. Injections with MesoHydral or Hydro Line Extra (in both groups) or Nucleospire DNA-RNA 2% (only in the LS group) were administered. All patients tolerated the procedures well, there were no side effects, and the patients were satisfied with the treatment.
Conclusion. Thus, preparations of this type can be recommended not only for practical use, but also for further, possibly more detailed and broad study of the spectrum of their capabilities.
Full Text
About the authors
A. S. Saidova
V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: i_apolikhina@oparina4.ru
Russian Federation, Moscow
A. R. Dudkina
V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: i_apolikhina@oparina4.ru
Russian Federation, Moscow
T. A. Teterina
V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: i_apolikhina@oparina4.ru
Russian Federation, Moscow
Inna A. Apolikhina
V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Sechenov University
Author for correspondence.
Email: i_apolikhina@oparina4.ru
ORCID iD: 0000-0002-4581-6295
Dr. Sci. (Med.), Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation; Professor at the Department of Obstetrics, Gynecology, Perinatology and Reproductology, Institute of Postgraduate Education
Russian Federation, Moscow; MoscowReferences
- Palacios S., Henderson V.W., Siseles N., et al. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric. 2010;13:419–28. doi: 10.3109/13697137.2010.507886.
- Tikhomirova E.V., Balan V.E., Fomina-Nilova O.S. Methods of treatment of genitourinary syndrome at the present stage. Meditsinskiy sovet. 2020;(13):91–6. (In Russ.).
- Apolikhina I.A., Gorbunova E.A. Clinical and morphological aspects of vulvovaginal atrophy. Meditsinskiy sovet. 2014;(9):110–7. (In Russ.).
- Portman D.J., Gass M.L. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Maturitas. 2014;79(3):349–54. doi: 10.1016/j.maturitas.2014.07.013.
- Sarmento A.C.A., Costa A.P.F., Vieira-Baptista P., et al. Genitourinary Syndrome of Menopause: Epidemiology, Physiopathology, Clinical Manifestation and Diagnostic. Front Reprod Health. 2021;3:779398.
- Shifren J.L. Genitourinary syndrome of menopause. Clin. Obstet. Gynecol. 2018;61:508–16.
- Draft clinical guidelines «Lichen sclerotic and atrophic». Moscow, 2020. (In Russ.)
- Paszkowski T., Binkowska M., Debski R., et al. Menopausal hormone therapy in questions and answers – a manual for physicians of various specialties. Prz Menopauzalny. 2019;18(1):1–8. doi: 10.5114/pm.2019.84150.
- Beauchamp P.J., Held B. Estrogen replacement therapy. Universal remedy for the postmenopausal woman? Postgrad Med. 1984;75(7):42–9, 52–3. doi: 10.1080/00325481.1984. 11698613.
- Judd H.L., Cleary R.E., Creasman W.T., et al. Estrogen replacement therapy. Obstet. Gynecol. 1981;58(3):267–75.
- Rossouw J.E., Anderson G.L., Prentice R.L., et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. doi: 10.1001/jama.288.3.321.
- Ravnikar V.A. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156(5):1332–4. doi: 10.1016/0002-9378(87)90173-6.
- Bollyky P.L., Falk B.A., Wu R.P., et al. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells. J Leukoc Biol. 2009;86:567–72. doi: 10.1189/jlb.0109001.
- Day A.J., de la Motte C.A. Hyaluronan crosslinking: a protective mechanism in inflammation? Trends Immunol. 2005;26:637–43. doi: 10.1016/j.it.2005.09.009.
- Aesthetic gynecology. Ed. by I.A. Apolikhina, G.T. Sukhikh. M., 2021. 656 p. (In Russ.). doi: 10.33029/9704-6569-1-ESG-2022-1-656.
- Jokar A., Davari T., Asadi N., et al. Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen Used in Treatment of Vaginal Atrophy of Menopause Women: A Randomized Controlled Clinical Trial. Int. J. Community Based Nurs Midwifery. 2016;4(1):69–78.
- Nappi R.E., Martella S., Albani F., et al. Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors? Healthcare (Basel). 2022;10(8):1528. doi: 10.3390/healthcare10081528.
- Berreni N., Salerno J., Chevalier T., et al. Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study. BMC Womens Health. 2021;21(1):322. Doi: 10.3390/ ph15121571.
- Kolczewski P., Parafiniuk M., Zawodny P., et al. Hyaluronic Acid and Radiofrequency in Patients with Urogenital Atrophy and Vaginal Laxity. Pharmaceuticals (Basel). 2022;15(12):1571. doi: 10.3390/ph15121571.
- Garavaglia E., Sala C., Busato M., et al. First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome. Med Devices (Auckl). 2020;13:399–410. doi: 10.2147/MDER.S275966.
- Angelucci M., Frascani F., Franceschelli A., et al. Efficacy of intradermal hyaluronic acid plus polynucleotides in vulvovaginal atrophy: a pilot study. Climacteric. 2022;25(5):490–96. doi: 10.1080/13697137.2022.2052840.
- Bogliatto F., Leidi L., Miletta M. Hyaluronic acid injection as functional adjuvant therapy in menopausal vulvovaginal symptoms – preliminary report. Work Paper Publ Health. 2016;5(1).
- Zarochentseva N.V., Dzhidzhikhiya L.K. Scleroatrophic lichen of the vulva: a modern view of the problem. Rossiiskii vestnik akushera-ginekologa. 2018;18(6):41–50. (In Russ.).
- Buzzaccarini G., Marin L., Noventa M., et al. Hyaluronic acid in vulvar and vaginal administration: evidence from a literature systematic review. Climacteric. 2021;24(6):560–71. doi: 10.1080/13697137.2021.1898580.
Supplementary files
